Development of clinical trial of new drugs of traditional Chinese medicines.
10.19540/j.cnki.cjcmm.20210302.501
- Author:
Zhong-Qi YANG
1
;
Ya-Qin TANG
1
;
Yan-Ping DU
1
;
Hui-Min TANG
1
;
Lei ZHANG
2
;
Rui GAO
3
;
Si-Yuan HU
4
;
Jian-Yuan TANG
5
;
Wei-An YUAN
6
Author Information
1. the First Affiliated Hospital of Guangzhou University of Chinese Medicine Guangzhou 510407, China.
2. Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
3. Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
4. First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin 300381, China.
5. Affiliated Hospital of Chengdu University of Traditional Chinese Medicine Chengdu 610075, China.
6. Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
- Publication Type:Journal Article
- Keywords:
clinical trial;
new drugs of traditional Chinese medicine;
overview
- MeSH:
China;
Drugs, Chinese Herbal;
Evidence-Based Medicine;
Humans;
Medicine, Chinese Traditional;
Syndrome
- From:
China Journal of Chinese Materia Medica
2021;46(7):1691-1695
- CountryChina
- Language:Chinese
-
Abstract:
The relevant laws and regulations of drug clinical trials were introduced in this paper. It is pointed out that with drug re-gulatory laws and technological advances, clinical trials have become an important link in the development of new drugs of traditional Chinese medicines(TCM). Clinical trials of new drugs of TCM must comply with the requirement of "Good Clinical Practice for Trial on Medicinal Products". In view of the particularities of clinical trials of new drugs of TCM, China has established an ethical review system for clinical research in TCM and carried out ethical review and certification of TCM research. In order to guide the development of clinical trials of new drugs of TCM, relevant departments have promulgated a series of guidelines for clinical trials of it, and established a new review system and technical requirements for clinical trials. Since 1983, the "national clinical pharmacology base" has been established. At present, there are 96 drug clinical trial institutions and 32 phase I clinical research wards in TCM hospitals, which can meet the development of clinical trials of new drugs of TCM. In the long-term practice, the technical team has continued to grow and develop, the research experience and technical strength have been significantly improved, and a large number of experts have become the backbone of clinical research in Chinese medicine. It is pointed out that we should attach importance to risk and benefit assessment, human experience, select scientific, objective and appropriate effectiveness indexes, evaluate the efficacy of TCM syndromes, and encourage the use of electronic methods in clinical research of new drugs of TCM. Based on the analysis of clinical trials of TCM in recent five years, it is pointed out that the active degree of clinical trials of new drugs of TCM is not high, the innovation ability of it is insufficient and the ability and enthusiasm of all aspects need to be improved. It is of great significance to carry out clinical trials of new traditional Chinese medicines to upgrade the TCM industry and produce high-level evidence-based medicine evidences. The high quality development of TCM can be promoted by strengthening clinical trials of new drugs of TCM.
